EcoDrugPlus

Serine/threonine-Protein Kinase Chk1-Like

Ensembl ID : ENSNBRG00000007143
Gene Symbol: LOC102790971
3 Cross references
177 Possible Orthologues:

Serine/threonine-Protein Kinase Plk4-Like

Ensembl ID : ENSNBRG00000007842
Gene Symbol: LOC102786138
3 Cross references
215 Possible Orthologues:

Serine/threonine-Protein Kinase Pim-1-Like

Ensembl ID : ENSNBRG00000002924
Gene Symbol: LOC102786254
3 Cross references
246 Possible Orthologues:

Serine/threonine-Protein Kinase Pim-3-Like

Ensembl ID : ENSNBRG00000023049
Gene Symbol: LOC102795893
3 Cross references
172 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSNBRG00000014342
Gene Symbol: LOC102777299
2 Cross references
408 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSNBRG00000015723
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
320 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1-Like

Ensembl ID : ENSNBRG00000010795
Gene Symbol: LOC102780319
3 Cross references
204 Possible Orthologues:

Smoothened Homolog

Ensembl ID : ENSNBRG00000004418
Gene Symbol: LOC102780724
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSNBRG00000016232
Gene Symbol: LOC102788469
3 Cross references
248 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSNBRG00000006146
Gene Symbol: SCN5LAB
1 Cross references
256 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSNBRG00000017323
Gene Symbol: SCN4A
4 Cross references
190 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSNBRG00000013577
Gene Symbol: SCN8A
4 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).